Share Name Share Symbol Market Type Share ISIN Share Description
Fulham Sho LSE:FUL London Ordinary Share GB00B9F8VG44 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.375p +2.86% 13.50p 13.25p 13.75p 13.50p 13.125p 13.125p 237,388 15:53:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Travel & Leisure 41.3 1.1 0.2 67.5 76.99

Fulham Sho (FUL) Latest News (1)

More Fulham Sho News
Fulham Sho Takeover Rumours

Fulham Sho (FUL) Share Charts

1 Year Fulham Sho Chart

1 Year Fulham Sho Chart

1 Month Fulham Sho Chart

1 Month Fulham Sho Chart

Intraday Fulham Sho Chart

Intraday Fulham Sho Chart

Fulham Sho (FUL) Discussions and Chat

Fulham Sho Forums and Chat

Date Time Title Posts
13/9/201715:28The Fulham Shore PLC65
26/7/201220:58Fulcrum Pharma - drug development to regulatory approval (1.1.07)631
21/2/200707:41FULCRUM IN PROFIT & GROWING1,807
17/4/200419:56Strong buy - FUL Pharma - profit and turnover up x 10 fold13
01/5/200309:14Fulcrum Pharma (FUL)1,061

Add a New Thread

Fulham Sho (FUL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-09-21 14:06:0213.4220,0002,684.00O
2017-09-21 14:04:3613.2515,0851,998.76O
2017-09-21 12:27:1813.13110,00014,437.50OK
2017-09-21 12:01:5713.2222,7003,000.94O
2017-09-21 11:00:3113.0030.39O
View all Fulham Sho trades in real-time

Fulham Sho (FUL) Top Chat Posts

DateSubject
21/9/2017
09:20
Fulham Sho Daily Update: Fulham Sho is listed in the Travel & Leisure sector of the London Stock Exchange with ticker FUL. The last closing price for Fulham Sho was 13.13p.
Fulham Sho has a 4 week average price of 12.75p and a 12 week average price of 12.75p.
The 1 year high share price is 22.75p while the 1 year low share price is currently 12.75p.
There are currently 570,269,265 shares in issue and the average daily traded volume is 326,004 shares. The market capitalisation of Fulham Sho is £76,986,350.78.
06/9/2017
11:21
lbo: http://uk.businessinsider.com/fulham-shore-share-price-franco-manca-profit-warning-sector-wide-slowdown-2017-9?r=US&IR=T
01/7/2017
08:26
topvest: Yes, maybe you are correct. It's definitely appealing to the young. It wasn't packed in Bournemouth on a Friday evening though. Surely, you can't deny that the valuation is a bit crazy at £109m? It should be making £5-10m of profits to have that sort of valuation. 50 or so restaurants and break even ish profitability doesn't merit that valuation at all. Barriers to entry are also rather low. Needs at least 2 years of growth to grow into its existing share price. Any disappointment and the shares will get hammered.
04/4/2017
07:52
utsushi: My penny's worth view-operationally the trading update was solid, earnings growth set to continue, the number of Franco Manca sites to increase to 45 by 2018, +50%, throwing off plenty of net cash, but high CAPEX, management good in Mr.Page, however valuation full, 13x EBITDA near term. Long term future positive for the company, but valuation risk if we enter a consumer lead down turn. The share price has a muted, positive tone, could drift higher-limited upside. No position-just a "ghost gambler".
07/11/2016
17:25
lbo: Tasty PLC just did a large fundraising which explains why it's share price has been falling all year. Is the same on the cards here?
28/4/2010
07:36
welsheagle: RNS Number : 9149K Fulcrum Pharma PLC 28 April 2010 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY RESTRICTED JURISDICTION (INCLUDING THE UNITED STATES, AUSTRALIA, CANADA AND JAPAN) OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 28 April 2010 RECOMMENDED CASH OFFER by GOLD MEDAL ACQUISITIONS UK LIMITED for FULCRUM PHARMA PLC Summary · The boards of Gold Medal Acquisitions UK Limited ("Gold Medal UK") and Fulcrum Pharma plc ("Fulcrum Pharma" or the "Company") are pleased to announce the terms of a recommended cash offer, to be made by Gold Medal UK for the entire issued and to be issued share capital of Fulcrum Pharma (the "Offer"). · The Offer will comprise 5.85 pence in cash for each Fulcrum Pharma Share (the "Offer Price"). · The Offer values the entire issued and to be issued share capital of Fulcrum Pharma at approximately £11.56 million. · The Offer Price represents a premium of approximately: o 73 per cent. to the Closing Price of 3.375 pence per Fulcrum Pharma Share on 27 April 2010, being the last Business Day prior to this Announcement; and o 83 per cent. to the average Closing Price of 3.20 pence per Fulcrum Pharma Share for the six month period ended 27 April 2010, being the last Business Day prior to this Announcement. · The Independent Directors, who have been so advised by Singer Capital Markets, consider the terms of the Offer to be fair and reasonable. In providing advice to the Independent Directors, Singer Capital Markets has taken into account the commercial assessments of the Independent Directors. · Accordingly, the Independent Directors intend unanimously to recommend that Fulcrum Pharma Shareholders accept the Offer. · The Fulcrum Pharma Directors have irrevocably undertaken with Gold Medal UK to accept, or procure the acceptance of, the Offer in respect of their entire beneficial holdings of Fulcrum Pharma Shares, which amount in aggregate to 11,114,563 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 6.25 per cent. of the current issued share capital of Fulcrum Pharma and in respect of any Fulcrum Pharma Shares that may be issued to, or acquired by, them pursuant to the exercise of options they hold over Fulcrum Pharma Shares. · Certain other Fulcrum Pharma Shareholders (not being Fulcrum Pharma Directors) have irrevocably undertaken to accept, or procure the acceptance of, the Offer in respect of certain of their respective beneficial holdings of Fulcrum Pharma Shares which amount, in aggregate, to 45,161,603 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 25.38 per cent. of the current issued share capital of Fulcrum Pharma. · In total, Fulcrum Pharma Shareholders have undertaken to accept, or procure the acceptance of, the Offer in respect of, in aggregate, 56,276,166 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 31.63 per cent. of the current issued share capital of Fulcrum Pharma. · Commenting on the Offer, Patrick K Donnelly (Executive Chairman of Gold Medal UK) said: "We are very excited about teaming up with the staff and management at Fulcrum Pharma due to their high level of expertise in drug development, regulatory submissions, drug safety services and consulting. In tandem with new capital from SV Life Sciences and The Halifax Group we look forward to significantly expanding the service offerings and geographic breadth of the Company as well as the career opportunities of the team." · Commenting on the Offer, Grahame Cook, Non-Executive Chairman of Fulcrum Pharma, said: "The acquisition of Fulcrum Pharma by Gold Medal UK is in the best interests of Fulcrum Pharma shareholders. Our small market capitalisation and our inflexible shareholder structure mean that there is very little liquidity in Fulcrum Pharma's shares and our share price is unlikely to reflect the company's value in the foreseeable future. We would like to make a number of identified acquisitions to add critical mass and expand our service offering. We have been unable to achieve the required equity funding from the stock market despite considerable efforts to do so. SV Life Sciences and The Halifax Group, Gold Medal UK's funders, are prepared to support this growth strategy. We have for these reasons concluded that the Offer, which represents a substantial premium to the current share price, is in the best interests of shareholders." This summary should be read in conjunction with, and is subject to, the full text of the following announcement (including the Appendices). The Offer will be subject to the Conditions and further terms set out in Appendix 1 to the following announcement and the terms and conditions to be set out in the Offer documentation, when issued. Appendix 2 contains the sources and bases of certain information used in this summary and in the following announcement. Appendix 3 contains definitions of certain terms used in this summary and the following announcement.
28/4/2010
07:31
welsheagle: Day prior to this Announcement; and o 83 per cent. to the average Closing Price of 3.20 pence per Fulcrum Pharma Share for the six month period ended 27 April 2010, being the last Business Day prior to this Announcement. · The Independent Directors, who have been so advised by Singer Capital Markets, consider the terms of the Offer to be fair and reasonable. In providing advice to the Independent Directors, Singer Capital Markets has taken into account the commercial assessments of the Independent Directors. · Accordingly, the Independent Directors intend unanimously to recommend that Fulcrum Pharma Shareholders accept the Offer. · The Fulcrum Pharma Directors have irrevocably undertaken with Gold Medal UK to accept, or procure the acceptance of, the Offer in respect of their entire beneficial holdings of Fulcrum Pharma Shares, which amount in aggregate to 11,114,563 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 6.25 per cent. of the current issued share capital of Fulcrum Pharma and in respect of any Fulcrum Pharma Shares that may be issued to, or acquired by, them pursuant to the exercise of options they hold over Fulcrum Pharma Shares. · Certain other Fulcrum Pharma Shareholders (not being Fulcrum Pharma Directors) have irrevocably undertaken to accept, or procure the acceptance of, the Offer in respect of certain of their respective beneficial holdings of Fulcrum Pharma Shares which amount, in aggregate, to 45,161,603 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 25.38 per cent. of the current issued share capital of Fulcrum Pharma. · In total, Fulcrum Pharma Shareholders have undertaken to accept, or procure the acceptance of, the Offer in respect of, in aggregate, 56,276,166 Fulcrum Pharma Shares, representing, as at the date of this Announcement, approximately 31.63 per cent. of the current issued share capital of Fulcrum Pharma. · Commenting on the Offer, Patrick K Donnelly (Executive Chairman of Gold Medal UK) said: "We are very excited about teaming up with the staff and management at Fulcrum Pharma due to their high level of expertise in drug development, regulatory submissions, drug safety services and consulting. In tandem with new capital from SV Life Sciences and The Halifax Group we look forward to significantly expanding the service offerings and geographic breadth of the Company as well as the career opportunities of the team." · Commenting on the Offer, Grahame Cook, Non-Executive Chairman of Fulcrum Pharma, said: "The acquisition of Fulcrum Pharma by Gold Medal UK is in the best interests of Fulcrum Pharma shareholders. Our small market capitalisation and our inflexible shareholder structure mean that there is very little liquidity in Fulcrum Pharma's shares and our share price is unlikely to reflect the company's value in the foreseeable future. We would like to make a number of identified acquisitions to add critical mass and expand our service offering. We have been unable to achieve the required equity funding from the stock market despite considerable efforts to do so. SV Life Sciences and The Halifax Group, Gold Medal UK's funders, are prepared to support this growth strategy. We have for these reasons concluded that the Offer, which represents a substantial premium to the current share price, is in the best interests of shareholders." This summary should be read in conjunction with, and is subject to, the full text of the following announcement (including the Appendices). The Offer will be subject to the Conditions and further terms set out in Appendix 1 to the following announcement and the terms and conditions to be set out in the Offer documentation, when issued. Appendix 2 contains the sources and bases of certain information used in this summary and in the following announcement. Appendix 3 contains definitions of certain terms used in this summary and the following announcement.
19/1/2010
15:36
ianctaylor: I considered buying shares in this company today but decided not to in the end. The share price is not stable enough for me. I prefer to see a smoother, more consistent price movement. I hope the preliminary approach made to the company in mid-November 2009 results in some benefit to holders. For what it's worth, a fair value per share would seem to be about 7p, with 177,940,743 shares in issue.
14/7/2009
14:54
gimeabreak: Had a feeling the share price would hike soon it had crashed without justification so just getting back to a semblance of its true value, that spread though has prevented me from buying more so so frustrating.
24/6/2009
19:15
gimeabreak: Nice one scruff if only if only. Really though if you read through the final results they appear quite positive when other companies are in financial difficulties laying off staff going bust Fulcrums performance is very good,which makes me wonder why the share price has taken such a battering as trading in this stock has been none existant nobody buying nobody selling, some hidden agenda whatever, I've held this stock for years and years never seen a profit, looks like another few more are to come before I'm rich rich RICH RICH HHHAAAAAA YIKKKEEESSSSSSS another tablet please doc
23/4/2009
13:50
platts: mountain man:re your question: I have held ful now for over 4 years and frankly the share price goes nowhere. at the same time the company continues to improve its performance - Japan etc. I wonder what needs to happen for this company to fall out of its bunker. I have no intention to sell (it's to cheap to do so.) I don't believe in pumping a stock as other people seem to want to do (see above)
Fulham Sho share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20170922 02:45:39